Press releases

8th December 2023

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

Data demonstrates METTL1 inhibition in vitro at low nanomolar concentrations while displaying high selectivity over other RNA and protein methyltransferases. Data provides the first proof-of-concept that pharmacological inhibition of a tRNA methyltransferase affects tumour growth in vitro and in animal models.

1st November 2023

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer.

17th October 2023

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

STORM’s first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase. STC-15 reshapes the tumour microenvironment and activates anti-tumour immunity.

9th August 2023

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference

STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development.

8th August 2023

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development.